Full Press Release Details
| Phone: 770-419-3355 | / Lynn Lewis |
| CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 | Gilmartin Group LLC Greg Chodaczek / Lynn Lewis Phone: 347-620-7010 investors@cryolife.com |
CryoLife Reports First Quarter 2020 Financial Results
First Quarter and Recent Business Highlights:
ATLANTA, GA (April 30, 2020) CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the first quarter ended March 31, 2020.
"During these challenging times, we are focused on protecting our employees' health and safety while continuing to supply our customers and patients who depend on our life saving and life sustaining products," commented Pat Mackin, Chairman, President, and Chief Executive Officer. "Our business is well suited to weather the impact of this global pandemic given the nature of the procedures in which our products are used. Our manufacturing facilities have been running at near capacity and our supply chain remained largely intact. We have continued to fund R&D programs related to products that could deliver revenue in 2021 and 2022, including our U.S. PerClot PMA, BioGlue China and PROACT Mitral. Further, we renegotiated our Credit Facility covenant to have greater financial flexibility, if necessary. Given our recent device approvals, and the ongoing progress made on our key growth initiatives, we expect 2021 to be a strong year for CryoLife.
First Quarter 2020 Financial Results
Total revenues for the first quarter of 2020 were $66.4 million, reflecting a decrease of (2%), and (1%) on a non-GAAP constant currency basis, both compared to the first quarter of 2019. Growth in tissue processing and On-X revenues was offset by decreases in BioGlue and JOTEC revenues.
Net loss for the first quarter of 2020 was ($6.7) million, or ($0.18) per fully diluted common share, compared to a net loss of ($297,000), or ($0.01) per fully diluted common share for the first quarter of 2019. Non-GAAP net loss for the first quarter of 2020 was ($3.0) million, or ($0.08) per fully diluted common share, compared to non-GAAP net income of $1.5 million, or $0.04 per fully diluted common share for the first quarter of 2019. Net loss on both a GAAP and non-GAAP basis reflects a $3.7 million pretax loss primarily related to non-cash unrealized foreign currency losses on intercompany payable balances.
2020 Financial Outlook
As previously reported on April 1, 2020, the Company has withdrawn its 2020 financial guidance due to uncertainties resulting from the COVID-19 pandemic.
All numbers are presented on a GAAP basis except where expressly referenced as non-GAAP. The Company does not provide GAAP income per common share on a forward-looking basis because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments, and any unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP.
The Company's financial performance for 2020 is subject to the risks identified below.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP net income and non-GAAP EBITDA results exclude (as applicable) business development and integration expenses, amortization expense, inventory basis step-up expense, loss on foreign currency revaluation, stock-based compensation expense, and corporate rebranding expenses. The Company believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions; the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses and the transaction and integration expenses incurred in connection with recently acquired and divested product lines; and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and stock-based compensation expense. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as acquisitions, or non-cash expense related to amortization of previously acquired tangible and intangible assets. The Company has excluded the impact of changes in currency exchange from certain revenues to evaluate growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the
future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur.
Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast later today, April 30, 2020 at 4:30 p.m. ET to discuss the results followed by a question and answer session. To listen to the live teleconference, please dial 201-689-8261. A replay of the teleconference will be available through May 7, 2020 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The Conference ID for the replay is 13702193.
The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations.
About CryoLife, Inc.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com.
Forward Looking Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs that our business is well suited to weather the impact of the COVID-19 pandemic given the nature of the procedures in which our products are used; that we are funding R&D programs for products that could deliver revenue in 2021 and 2022, including our U.S. PerClot PMA, BioGlue China, and PROACT Mitral; that the renegotiation of our Credit Facility covenant will give us greater financial flexibility, if necessary; and that we expect 2021 to be a strong year for CryoLife. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for year ended December 31, 2019. CryoLife does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.
CryoLife, Inc. and Subsidiaries
Financial Highlights
(In thousands, except per share data)
| Three Months Ended | |||||
| March 31, | |||||
| 2020 | 2019 | ||||
| Revenues: | |||||
| Products | $ | 46,420 | $ | 48,401 | |
| Preservation services | 20,009 | 19,104 | |||
| Total revenues | 66,429 | 67,505 | |||
| Cost of products and preservation services: | |||||
| Products | 13,040 | 13,826 | |||
| Preservation services | 9,218 | 9,406 | |||
| Total cost of products and preservation services | 22,258 | 23,232 | |||
| Gross margin | 44,171 | 44,273 | |||
| Operating expenses: | |||||
| General, administrative, and marketing | 39,002 | 36,520 | |||
| Research and development | 6,356 | 5,548 | |||
| Total operating expenses | 45,358 | 42,068 | |||
| Operating (loss) income | (1,187) | 2,205 | |||
| Interest expense | 3,388 | 3,894 | |||
| Interest income | (102) | (116) | |||
| Other expense, net | 3,662 | 77 | |||
| Loss before income taxes | (8,135) | (1,650) | |||
| Income tax benefit | (1,470) | (1,353) | |||
| Net loss | $ | (6,665) | $ | (297) | |
| Loss per common share: | |||||
| Basic | $ | (0.18) | $ | (0.01) | |
| Diluted | $ | (0.18) | $ | (0.01) | |
| Weighted-average common shares outstanding: | |||||
| Basic | 37,390 | 36,778 | |||
| Diluted | 37,390 | 36,778 | |||
| Net loss | $ | (6,665) | $ | (297) | |
| Other comprehensive loss: | |||||
| Foreign currency translation adjustments | (4,463) | (3,781) | |||
| Comprehensive loss | $ | (11,128) | $ | (4,078) |
CryoLife, Inc. and Subsidiaries
Financial Highlights
| (Unaudited) | |||||
| Three Months Ended | |||||
| March 31, | |||||
| 2020 | 2019 | ||||
| Products: | |||||
| BioGlue | $ | 16,737 | $ | 17,222 | |
| JOTEC | 15,268 | 15,954 | |||
| On-X | 12,202 | 11,731 | |||
| PhotoFix | 1,042 | 730 | |||
| PerClot | 860 | 1,050 | |||
| NEXUS | 200 | -- | |||
| CardioGenesis cardiac laser therapy | 111 | 1,714 | |||
| Total products | 46,420 | 48,401 | |||
| Preservation services: | |||||
| Cardiac tissue | $ | 10,033 | $ | 8,930 | |
| Vascular tissue | 9,976 | 10,174 | |||
| Total preservation services | 20,009 | 19,104 | |||
| Total revenues | $ | 66,429 | $ | 67,505 | |
| Revenues: | |||||
| U.S. | $ | 36,447 | $ | 37,325 | |
| International | 29,982 | 30,180 | |||
| Total revenues | $ | 66,429 | $ | 67,505 |
| (Unaudited) | |||||
| March 31, | December 31, | ||||
| 2020 | 2019 | ||||
| Cash, cash equivalents, and restricted securities | $ | 63,877 | $ | 34,294 | |
| Total current assets | 214,082 | 187,390 | |||
| Total assets | 621,033 | 605,654 | |||
| Total current liabilities | 43,685 | 45,195 | |||
| Total liabilities | 344,424 | 319,958 | |||
| Shareholders' equity | 276,609 | 285,696 |
CryoLife, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
Net Loss and Diluted (Loss) Income Per Common Share
(In thousands, except per share data)
| (Unaudited) | |||||
| Three Months Ended | |||||
| March 31, | |||||
| 2020 | 2019 | ||||
| GAAP: | |||||
| Loss before income taxes | $ | (8,135) | $ | (1,650) | |
| Income tax benefit | (1,470) | (1,353) | |||
| Net loss | $ | (6,665) | $ | (297) | |
| Diluted loss per common share: | $ | (0.18) | $ | (0.01) | |
| Reconciliation of loss before income taxes, | |||||
| GAAP to adjusted net (loss) income, non-GAAP | |||||
| Loss before income taxes, GAAP | $ | (8,135) | $ | (1,650) | |
| Adjustments: | |||||
| Amortization expense | 3,033 | 2,579 | |||
| Business development and integration expenses | 823 | 1,109 | |||
| Corporate rebranding | 321 | -- | |||
| Adjusted (loss) income before income taxes, | |||||
| non-GAAP | (3,958) | 2,038 | |||
| Income tax expense calculated at a | |||||
| pro forma tax rate of 25% | (989) | 510 | |||
| Adjusted net (loss) income, non-GAAP | $ | (2,969) | $ | 1,528 | |
| Reconciliation of diluted loss per common share, GAAP | |||||
| to adjusted diluted (loss) income per common share, non-GAAP: | |||||
| Diluted loss per common share, GAAP: | $ | (0.18) | $ | (0.01) | |
| Adjustments: | |||||
| Amortization expense | 0.08 | 0.07 | |||
| Business development and integration expenses | 0.02 | 0.03 | |||
| Corporate rebranding | 0.01 | -- | |||
| Tax effect of non-GAAP adjustments | (0.03) | (0.03) | |||
| Effect of 25% pro forma tax rate | 0.02 | (0.02) | |||
| Adjusted diluted (loss) income per common share, | |||||
| non-GAAP: | $ | (0.08) | $ | 0.04 | |
| Diluted weighted-average common | |||||
| shares outstanding | 37,390 | 37,711 |
CryoLife, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
(In thousands, except per share data)
| (Unaudited) | ||||||
| Three Months Ended | ||||||
| March 31, | ||||||
| 2020 | 2019 | Growth Rate | ||||
| Reconciliation of total revenues, GAAP to | ||||||
| total revenues, non-GAAP: | ||||||
| Total revenues, GAAP | $ | 66,429 | $ | 67,505 | -2% | |
| Impact of changes in currency exchange | -- | (629) | ||||
| Total constant currency revenues, non-GAAP | $ | 66,429 | $ | 66,876 | -1% | |
| Reconciliation of total revenues, GAAP to | ||||||
| total revenues, non-GAAP: | ||||||
| Total revenues, GAAP | $ | 66,429 | $ | 67,505 | -2% | |
| Less CardioGenesis cardiac laser therapy | (111) | (1,714) | ||||
| Total GAAP revenues excluding CardioGenesis | 66,318 | 65,791 | 1% | |||
| Impact of changes in currency exchange | -- | (629) | ||||
| Total constant currency revenues excluding CardioGenesis, non-GAAP | $ | 66,318 | $ | 65,162 | 2% | |
| Reconciliation of total BioGlue revenues, GAAP to | ||||||
| total BioGlue revenues, non-GAAP: | ||||||
| Total BioGlue revenues, GAAP | $ | 16,737 | $ | 17,222 | -3% | |
| Impact of changes in currency exchange | -- | (76) | ||||
| Total constant currency BioGlue revenues, non-GAAP | $ | 16,737 | $ | 17,146 | -2% | |
| Reconciliation of total On-X revenues, GAAP to | ||||||
| total On-X revenues, non-GAAP: | ||||||
| Total On-X revenues, GAAP | $ | 12,202 | $ | 11,731 | 4% | |
| Impact of changes in currency exchange | -- | (17) | ||||
| Total constant currency On-X revenues, non-GAAP | $ | 12,202 | $ | 11,714 | 4% | |
| Reconciliation of total JOTEC revenues, GAAP, to | ||||||
| total JOTEC revenues, non-GAAP: | ||||||
| Total JOTEC revenues, GAAP | $ | 15,268 | $ | 15,954 | -4% | |
| Impact of changes in currency exchange | -- | (534) | ||||
| Total constant currency JOTEC revenues, non-GAAP | $ | 15,268 | $ | 15,420 | -1% |
CryoLife, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
(In thousands, except per share data)
| (Unaudited) | |||||
| Three Months Ended | |||||
| March 31, | |||||
| 2020 | 2019 | ||||
| Reconciliation of net loss, GAAP to | |||||
| adjusted EBITDA, non-GAAP: | |||||
| Net loss, GAAP | $ | (6,665) | $ | (297) | |
| Adjustments: | |||||
| Depreciation and amortization expense | 4,898 | 4,350 | |||
| Loss on foreign currency revaluation | 3,663 | 74 | |||
| Interest expense | 3,388 | 3,894 | |||
| Stock-based compensation expense | 2,564 | 1,853 | |||
| Business development and integration expenses | 823 | 1,109 | |||
| Corporate rebranding | 321 | -- | |||
| Interest income | (102) | (116) | |||
| Income tax benefit | (1,470) | (1,353) | |||
| Adjusted EBITDA, non-GAAP | $ | 7,420 | $ | 9,514 |